Please assess the completion status of the following clinical trial:

Trial Title: Combination Antibiotic Treatment for Reactive Arthritis Caused by Chlamydia Bacteria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Meet the following European Spondyloarthropathy Study Group Criteria:~  1. inflammatory spinal pain OR~ 2. synovitis AND~ 3. one or more of the following:~     1. positive family history~    2. urethritis or cervicitis within 1 month prior to onset of arthritis~    3. buttock pain~    4. enthesopathy~    5. sacroiliitis~* Disease duration of at least 6 months~* Negative pregnancy test at study baseline and willing to use an effective method of contraception other than combined oral contraceptives for the duration of the study (for women of childbearing age)~Exclusion Criteria:~* Sensitivity or history of allergic reaction to rifampin, doxycycline, or azithromycin~* Currently taking any medications that may interact with the study medications, specifically rifampin~* Liver transaminases greater than or equal to two times the normal level~* Significant abnormalities in the complete blood count (CBC)~* Pregnant~* Current psoriasis~* Diagnosis of inflammatory bowel disease~* Diagnosis of ankylosing spondylitis~* Previous prolonged exposure to antibiotics (more than 2 weeks) as a potential treatment for reactive arthritis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Azithromycin and Rifampin (Type: ACTIVE_COMPARATOR): Participants received Azithromycin and Rifampin
- Doxycycline and Rifampin (Type: ACTIVE_COMPARATOR): Participants received Doxycycline and Rifampin
- received placebo (Type: PLACEBO_COMPARATOR): Participants received placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).